DGNOF
DIAGNOS Inc.·Healthcare
0.18
4.141%(−0.01)
Market ClosedLast Updated: — ET
52W L: $0.1352W H: $0.29
DGNOF NEWS
globenewswire.com
3d ago
DIAGNOS Provides an Update on Sales and Regulatory Activities for CARA
BROSSARD, Quebec, April 08, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to provide an update to the press release dated January 13, 2026 on the regulatory pathway for the future version of its flagship product CARA, which incorporates eye-related disease detection algorithms, and April 1, 2026 announcement regarding U.S. establishment registration renewal and the continued U.S. commercialization status of the legacy version of CARA.
globenewswire.com
Apr 1
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
BROSSARD, Quebec, April 01, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA) has been successfully completed.
defenseworld.net
Mar 19
DIAGNOS (OTCMKTS:DGNOF) Trading Up 2.6% – Time to Buy?
Shares of DIAGNOS Inc. (OTCMKTS:DGNOF - Get Free Report) shot up 2.6% during trading on Wednesday. The stock traded as high as $0.2145 and last traded at $0.2125. 25,000 shares were traded during mid-day trading, a decline of 72% from the average session volume of 88,814 shares. The stock had previously closed at $0.2072.
globenewswire.com
Mar 5
DIAGNOS Announces Amendments to Convertible Debentures and Stock Warrants
BROSSARD, Quebec, March 05, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the terms of an aggregate amount of $510,000 of unsecured convertible debentures (each, a Debenture) issued as part of a non-brokered private placement of units initially announced on March 1, 2022, and subsequently amended on March 1, 2025 (pleaser refer to the press release dated February 28, 2025). The amendments are as follows:
globenewswire.com
Feb 24
DIAGNOS to present at Centurion One Capital 9th Annual Toronto Growth Conference
BROSSARD, Quebec, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical eye-related health issues using advanced technology based on Artificial Intelligence (AI), is pleased to announce that it will be presenting at the Centurion One Capital 9th Annual Conference in Toronto, Canada March 5th 2026.
defenseworld.net
Feb 18
DIAGNOS (OTCMKTS:DGNOF) Trading 1.6% Higher – Still a Buy?
DIAGNOS Inc. (OTCMKTS:DGNOF - Get Free Report)'s share price traded up 1.6% during trading on Tuesday. The company traded as high as $0.2189 and last traded at $0.2175. 300,800 shares were traded during trading, an increase of 261% from the average session volume of 83,233 shares. The stock had previously closed at $0.2140. DIAGNOS
